8-K 1 v82645e8vk.htm FORM 8-K Bioject Medical Technologies Inc. Form 8-K
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 1, 2002

BIOJECT MEDICAL TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)
         
Oregon   0-15360   93-1099680
 
 
(State or other jurisdiction
of incorporation)		   (Commission
File Number) 		  (IRS Employer
Identification No.)
 
211 Somerville Road (Route 202 North), Bedminster, NJ       07921
     
(Address of principal executive offices)       (Zip code)

Registrant’s telephone number, including area code: (908) 470-2800

Former name or former address, if changed since last report: 7620 S.W. Bridgeport Road, Portland, OR 97224

 

Item 5. Other Events and Regulation FD Disclosure
Item 7. Financial Statements and Exhibits.
SIGNATURE
EXHIBIT INDEX
Exhibit 4
Exhibit 99

Table of Contents

INFORMATION TO BE INCLUDED IN THE REPORT

Item 5. Other Events and Regulation FD Disclosure

     On July 2, 2002, the Board of Directors of Bioject Medical Technologies Inc. announced that it has adopted a shareholder rights agreement. A press release relating to the agreement and the agreement are filed as exhibits to this report.

Item 7. Financial Statements and Exhibits.

     (c)  Exhibits.

     
Exhibit Number   Exhibit Title
 
 
  4   Rights Agreement, dated as of July 1, 2002, between the Company and American Stock Transfer & Trust Company, including Exhibit A Terms of the Preferred Stock, Exhibit B Form of Rights Certificate, and Exhibit C Summary of the Right To Purchase Preferred Stock.
 
99   Press Release, dated as of July 2, 2002.

2

Table of Contents

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
     
    BIOJECT MEDICAL TECHNOLOGIES INC.
 
 
    /s/ JOHN GANDOLFO
 
  John Gandolfo
Chief Financial Officer
(Principal Financial and Accounting Officer)

Dated: July 2, 2002.

3

Table of Contents

EXHIBIT INDEX

     
Exhibit Number   Exhibit Title
 
 
  4   Rights Agreement, dated as of July 1, 2002, between the Company and American Stock Transfer & Trust Company, including Exhibit A Terms of the Preferred Stock, Exhibit B Form of Rights Certificate, and Exhibit C Summary of the Right To Purchase Preferred Stock.
 
99   Press Release, dated as of July 2, 2002.

4